Acer Therapeutics Competitors, Revenue and Alternatives
Estimated Revenue & Financials
- Acer Therapeutics's estimated annual revenue is currently $5M per year.
- Acer Therapeutics received $11.0M in venture funding in December 2017.
- Acer Therapeutics's estimated revenue per employee is $122,561
- Acer Therapeutics's total funding is $29M.
- Acer Therapeutics has 41 Employees.
- Acer Therapeutics grew their employee count by 21% last year.
- Acer Therapeutics currently has 1 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Vita Data Scien...||$10.3M||51||50%||N/A|
What Is Acer Therapeutics?
Acer Therapeutics Inc. (Nasdaq: ACER) is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with critical unmet medical need. Founded in 2013, Acer completed its Initial Public Offering in 2017, has raised $87M to date, and has rapidly built a diverse portfolio of product candidates. Our pipeline includes three clinical-stage candidates: EDSIVO (celiprolol) for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; ACER-001 (a fully taste-masked, immediate release formulation of sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCD) and Maple Syrup Urine Disease (MSUD); and osanetant for the treatment of various neuroendocrine disorders. On December 26, 2018 the U.S. Food and Drug Administration (FDA) accepted for review Acer's New Drug Application (NDA) for EDSIVO for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed COL3A1 mutation. The FDA also granted a priority review of the NDA and assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 25, 2019. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Acer's strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency. Acer has a strong company culture and is committed to creating and maintaining an environment that values individual rights, hard work, fosters creativity, and promotes success. The Company is growing rapidly and is fueled by the talent and expertise of our employees, driven by the commitment to treating patients with critical unmet medical needs.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
|Jason Kneeland||VP Finance, Controller||Email Available|
|Will Andrews||Chief Medical Officer||Email Available|
|Jim DeNike||Executive Director, Investor Relations|
|Kristin Mulready||Vice President, Program & Alliance Management|
|Eric VanVactor||Director Of Manufacturing|
|Darren Allender||Director, Commercial Operations||Email Available|
|Srinivas Tetali||Vice President Medical Affairs|
|Don Joseph||Chief Legal Officer||Email Available|
|Terrie Burrell||Vice President, Clinical Science|
|Stacey Bain||Vice President Clinical Operations|
Acer Therapeutics News
13, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development ...
Acer Therapeutics Inc. (NASDAQ: ACER) ("Acer" or the "Company") is a pharmaceutical company headquartered in Newton, Massachusetts, ...
Acer Therapeutics (NASDAQ:ACER) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report ...
Acer Therapeutics Funding
|2016-05-11||$8.2M||B||TVM Life Science Venture VII||Article|
|2017-12-18||$11.0M||Undisclosed||William Blair & Company, L.L.C.||Article|
Acer Therapeutics Executive Hires
|2017-10-06||William Andrews||Chief Medical Officer||Article|
|2018-02-06||Terrie Kellmeyer||Vice President, Clinical Science||Article|
|2018-12-18||Salma Jutt||Chief Commercial Officer||Article|